Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?
John McHutchison* and Amany Zekry
Correspondence *Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Centre, Durham, NC, 27705, USA.
Email mchut001@mc.duke.edu
This article has no abstract so we have provided the first paragraph of the full text.
In the HIV population, the accelerated progression of HCV-related liver disease has emerged as an important cause of morbidity and mortality.1 Initial trials in HCV and HIV coinfected patients receiving IFN monotherapy, or standard IFN and ribavirin combination therapy, indicated SVR rates of 13–40%.2 Subsequent large-scale studies in HCV monoinfected patients have shown an improved SVR3, 4 among patients receiving combination pegIFN and ribavirin therapy. According to two recent studies, the enhanced virologic efficacy of this regimen extends to patients coinfected with HCV and HIV. In the APRICOT TRIAL, coinfected patients receiving this therapy had a higher SVR (40%); with the best response rates achieved among patients infected with HCV genotype 2 or 3.
Full text of this article is available with one of the following:
- Membership of the American College of Gastroenterology. If already a member, please login.
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
